Here, we describe a case of 76-year-old Asian woman with platinum-resistant recurrent ovarian cancer, characterized by high FRα expression (95%, 3 + intensity), who achieved a complete response following treatment with Mirvetuximab Soravtansine after undergoing multiple prior therapies. The gene discussed is FOLR1; the disease is ovarian carcinoma.